SCHEMBL2235392

SCHEMBL2235392

COC(=O)NN(C(=O)Oc1ccccc1)c1ccccc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
PTGES O14684 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 3/20 0.40
HTT P42858 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
GFER P55789 1/20 0.40
LIPE Q05469 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
STAT3 P40763 1/20 0.39
TSPO P30536 1/20 0.38
RAB9A P51151 1/20 0.37
HTR1A P08908 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2232497 0.91 MAPT (0.41) POLBPTGESATMKMT2AMEN1
SCHEMBL2232860 0.90 ATM (0.44) POLBATML3MBTL1KMT2AHTT
SCHEMBL2236294 0.90 ATM (0.47) POLBATML3MBTL1KMT2AALDH1A1
SCHEMBL2237995 0.89 HPGD (0.41) POLBPTGESKMT2AALDH1A1MEN1
SCHEMBL2236089 0.86 ALDH1A1 (0.43) POLBPTGESKMT2AALDH1A1MEN1
SCHEMBL2233414 0.86 LIPE (0.53) KMT2AMEN1MAPTLIPERAB9A
SCHEMBL2233290 0.85 ALDH1A1 (0.50) ATMKMT2AHTTALDH1A1MEN1
SCHEMBL2235417 0.85 KMT2A (0.43) TDP1L3MBTL1KMT2AHTTALDH1A1
SCHEMBL2234563 0.84 KDM4E (0.43) L3MBTL1KMT2AALDH1A1MEN1KDM4E
SCHEMBL2232541 0.83 TACR3 (0.43) PTGESTDP1ATML3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR POLB 2483/4885PTGES 1865/4885TDP1 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.